Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) was the target of unusually large options trading on Monday. Traders acquired 10,082 put options on the company. This is an increase of 533% compared to the typical daily volume of 1,592 put options.
Ginkgo Bioworks Stock Performance
NYSE:DNA opened at $8.49 on Tuesday. The stock’s fifty day moving average price is $10.33 and its two-hundred day moving average price is $8.63. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $18.22.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.04. Ginkgo Bioworks had a negative return on equity of 56.97% and a negative net margin of 249.20%. The company had revenue of $27.71 million during the quarter, compared to analysts’ expectations of $21.50 million.
Analysts Set New Price Targets
Several equities analysts recently weighed in on DNA shares. Wall Street Zen raised shares of Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Thursday, October 15th. BTIG Research restated a “sell” rating and issued a $5.00 target price on shares of Ginkgo Bioworks in a report on Friday, September 4th. Oppenheimer set a $5.00 target price on Ginkgo Bioworks in a report on Wednesday, September 9th. Finally, TD Cowen upped their price target on Ginkgo Bioworks from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Two equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $7.00.
View Our Latest Stock Report on DNA
Insider Transactions at Ginkgo Bioworks
In other news, insider Reshma Shetty sold 18,803 shares of the business’s stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $10.14, for a total transaction of $190,662.42. Following the completion of the sale, the insider owned 356,329 shares in the company, valued at $3,613,176.06. The trade was a 5.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jason Kelly sold 45,682 shares of the firm’s stock in a transaction on Monday, October 19th. The shares were sold at an average price of $10.14, for a total transaction of $463,215.48. Following the completion of the transaction, the insider directly owned 129,065 shares in the company, valued at $1,308,719.10. This trade represents a 26.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 136,525 shares of company stock valued at $1,379,699. Company insiders own 12.69% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the stock. Entropy Technologies LP boosted its position in shares of Ginkgo Bioworks by 374.5% in the third quarter. Entropy Technologies LP now owns 66,279 shares of the company’s stock valued at $850,000 after acquiring an additional 52,311 shares during the period. FORA Capital LLC bought a new stake in Ginkgo Bioworks during the 3rd quarter worth approximately $405,000. Caxton Associates LLP lifted its stake in Ginkgo Bioworks by 16.7% in the 3rd quarter. Caxton Associates LLP now owns 180,444 shares of the company’s stock worth $2,315,000 after purchasing an additional 25,797 shares in the last quarter. Q Fund Management Hong Kong Ltd purchased a new stake in Ginkgo Bioworks in the 3rd quarter worth approximately $505,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Ginkgo Bioworks in the 2nd quarter worth approximately $50,000. Hedge funds and other institutional investors own 78.63% of the company’s stock.
About Ginkgo Bioworks
Ginkgo Bioworks is a biotechnology company that develops and engineers microorganisms and other cells for use in commercial products. Its platform combines biological research, automation, and software to help customers design, build, and test organisms with desired characteristics. The company provides cell-engineering services and capabilities to organizations in areas including pharmaceuticals, agriculture, food, and industrial chemicals. Its work can include developing and optimizing microbial strains and supporting the production of ingredients and other materials.
Featured Stories
- Five stocks we like better than Ginkgo Bioworks
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
